Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Researchers explore link between workplace stress and exposure on GI disorders

In two new studies, presented at the American College of Gastroenterology's (ACG) 74th Annual Scientific meeting in San Diego, researchers explored the connection between high stress, high exposure occupations and long-term gastrointestinal disorders.

27 Oct 2009

Study reveals LOAD therapy can eliminate bacterium in patients with gastritis and peptic ulcers

Helicobater pylori, a bacteria implicated in peptic ulcers and gastritis, was eradicated in 95 percent patients who took a 7-day course of combination therapy with levofloxacin, omeprazole, nitazoxanide (Alinia®) and doxycycline (LOAD) compared to eradication in only 80.9 percent of patients on lansoprazole, amoxicillin and clarithromycin (LAC) for seven days.

27 Oct 2009

Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution

Gilead Sciences, Inc. today announced that aztreonam for inhalation solution, an investigational product for the treatment of infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF), is scheduled to be reviewed by the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on December 10, 2009.

27 Oct 2009

Stomach infection on the rise in outpatient settings; symptoms can range from diarrhea to life-threatening inflammation

Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile, (http://www.mayoclinic.org/c-difficile/) is on the rise in outpatient settings.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

HHS funds $17M for fight against costly and dangerous health care-associated infections

HHS Secretary Kathleen Sebelius today announced the award of $17 million to fund projects to fight costly and dangerous health care-associated infections, or HAIs.

24 Oct 2009

Findings may lead to new vaccine strategies for pulmonary tularemia

Immunologists at the University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC and the have found a unique quirk in the way the immune system fends off bacteria called Francisella tularensis, which could lead to vaccines that are better able to prevent tularemia infection of the lungs. Their findings were published today in the early, online version of Immunity.

23 Oct 2009

In vitro activity results of Cem-101 against gram-positive organisms to be presented

Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America, 47th Annual Meeting, in Philadelphia on Oct. 29 to Nov. 1, 2009.

23 Oct 2009

Gen-Probe acquires Prodesse

Gen-Probe announced today that the Company has completed its acquisition of Prodesse, Inc., a leader in molecular testing for influenza and other infectious diseases, for approximately $60 million in cash.

23 Oct 2009

Theravance earns milestone payment for bactericidal, injectable lipoglycopeptide antibiotic

Theravance, Inc. announced today that it has earned a milestone payment of $20 million for the U.S. Food and Drug Administration (FDA) approval of VIBATIV (telavancin) and supplying its collaboration partner, Astellas Pharma US, Inc. (Astellas), with the launch inventory for the first commercial sale in the United States.

23 Oct 2009

American Thoracic Society releases new clinical guidelines for pulmonary exacerbation of cystic fibrosis

The American Thoracic Society has released new clinical guidelines for the treatment of exacerbations in cystic fibrosis based on a review of the literature on current clinical practices.

23 Oct 2009

Eat healthy food to keep bacteria in the gut healthy

Healthy eating, not supplements, is the best way to keep the good bacteria in your gut healthy, says a dietitian and researcher.

22 Oct 2009

Study compares effects of clin-BPO 2.5% and clin-BPO 5% on epidermal functions

Dermatologists agree that topical fixed-combination products containing clindamycin (clin) and benzoyl peroxide (BPO) are effective in the treatment of acne. However, products containing BPO concentrations at 5% or higher may limit use due to associated dryness and irritation in some patients.

22 Oct 2009

Optimer Pharmaceuticals to present additional data on fidaxomicin at the 47th IDSA meeting

Optimer Pharmaceuticals, Inc. announced that additional data related to fidaxomicin, the Company's lead developmental product candidate for the treatment of Clostridium difficile infection, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at The Philadelphia Convention Center in Philadelphia, Pennsylvania October 29 through November 1, 2009.

20 Oct 2009

Positive results from Transave's Phase II ARIKACE clinical trials

Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.

20 Oct 2009

Study on the economic impact of antibiotic overuse and antibiotic-resistant infections

The Alliance for the Prudent Use of Antibiotics (APUA) and Cook County Hospital (currently John H. Stroger, Jr. Hospital of Cook County), today announced the release of an eye-opening study on the economic impact of antibiotic overuse and antibiotic-resistant infections (ARIs) sponsored by an unrestricted educational grant from bioMerieux and the Centers for Disease Control and Prevention (CDC).

19 Oct 2009

TheraDoc commences beta testing of new computerized patient surveillance tool

TheraDoc®, the leading provider of clinical decision support technology in healthcare, today announced that it has started beta testing of a new computerized patient surveillance tool that will help hospitals monitor and manage screening programs for multidrug-resistant organisms (MDROs), such as methicillin-resistant Staphylococcus aureus, or MRSA, which every year kills more people in the United States than AIDS.

19 Oct 2009

Antibiotic resistance to be undesirable consequence of antibiotic abuse is inaccurate, reveals report

The perception that antibiotic resistance is primarily the undesirable consequence of antibiotic abuse or misuse is a view that is simplistic and inaccurate, according to a recent report by the American Academy of Microbiology. The reasons behind the spread of resistance are much more complex, including appropriate antibiotic use, lack of proper sanitation and hygiene, and even the environment.

19 Oct 2009

PHARMACIA & UPJOHN COMPANY to pay the largest criminal fine ever imposed in the U.S.

PHARMACIA & UPJOHN COMPANY, INC., a subsidiary of Pfizer Inc. ("Pfizer") today was sentenced today in federal court for a felony violation of the Food, Drug & Cosmetic Act, for misbranding the drug, Bextra, with the intent to defraud or mislead.

19 Oct 2009

Multi-million dollar cooperative agreement for SMA drug development program

Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS).

19 Oct 2009

Antibiotic News and Research

Further Reading

Researchers explore link between workplace stress and exposure on GI disorders

Study reveals LOAD therapy can eliminate bacterium in patients with gastritis and peptic ulcers

Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution

Stomach infection on the rise in outpatient settings; symptoms can range from diarrhea to life-threatening inflammation

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

HHS funds $17M for fight against costly and dangerous health care-associated infections

Findings may lead to new vaccine strategies for pulmonary tularemia

In vitro activity results of Cem-101 against gram-positive organisms to be presented

Gen-Probe acquires Prodesse

Theravance earns milestone payment for bactericidal, injectable lipoglycopeptide antibiotic

American Thoracic Society releases new clinical guidelines for pulmonary exacerbation of cystic fibrosis

Eat healthy food to keep bacteria in the gut healthy

Study compares effects of clin-BPO 2.5% and clin-BPO 5% on epidermal functions

Optimer Pharmaceuticals to present additional data on fidaxomicin at the 47th IDSA meeting

Positive results from Transave's Phase II ARIKACE clinical trials

Study on the economic impact of antibiotic overuse and antibiotic-resistant infections

TheraDoc commences beta testing of new computerized patient surveillance tool

Antibiotic resistance to be undesirable consequence of antibiotic abuse is inaccurate, reveals report

PHARMACIA & UPJOHN COMPANY to pay the largest criminal fine ever imposed in the U.S.

Multi-million dollar cooperative agreement for SMA drug development program

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News